Put companies on watchlist
Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News (77 News)
Country: Germany · Primary market: Germany · EQS NID: 2000683
02 October 2024 11:06AM

Alzchem Group AG plans to double nitroguanidine production capacity in Germany


EQS-News: Alzchem Group AG / Key word(s): Miscellaneous
Alzchem Group AG plans to double nitroguanidine production capacity in Germany

02.10.2024 / 11:06 CET/CEST
The issuer is solely responsible for the content of this announcement.


Alzchem Group AG plans to double nitroguanidine production capacity in Germany

Trostberg, October 2, 2024 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, plans to significantly increase its production capacity for nitroguanidine. It was only in spring of this year that the company announced a capacity expansion for the preliminary stage with an investment of EUR 76 million over several years. Taking into account the additional expansion plans for a new production plant, the total investment will almost double. Alzchem expects this to result in increasing revenues in the upper double-digit million range from 2027 onwards, with correspondingly positive contributions to earnings. To this end, supply contracts have already been signed with several customers in the defense sector, who have declared their willingness to make significant contributions to the financing of the new plant in the common interest. The new production capacities are expected to be commissioned in the second half of 2026.

As part of this investment, the largest in the company’s history, Alzchem will not only build a new nitroguanidine production plant but also renew and expand the existing facilities for the production of guanidine nitrate, the precursor of nitroguanidine. For this first investment project, the company was already awarded an investment grant of EUR 34.4 million by the EU Commission in March of this year as part of the ASAP (“Act in Support of Ammunition Production”) funding instrument (see ad hoc announcement dated March 15, 2024).

Andreas Niedermaier, CEO of Alzchem Group AG: “The planned measures will lead to further profitable growth for Alzchem. The fact that we are able to implement the largest investment in our company’s history in Germany to date is not least thanks to our customers, who will continue to support us closely on our way with their financing commitments. This cannot be taken for granted in view of the persistently difficult conditions. We are proud of this proof of confidence.”

In parallel to the measures in Germany, Alzchem will intensify its site search in the USA. To this end, a preliminary contract has been concluded with the US Department of Defense that extends over the next two years. In the event that a suitable production site is found during this period, the US Department of Defense has already committed USD 150 million in funding for the construction of a production facility in the US by the end of 2029. Dr. Georg Weichselbaumer, CSO of Alzchem Group AG comments: “It is a great success for us that we can raise the now approved investments as well as possible further investments in the U.S. without additional equity capital. Demand for nitroguanidine, which is used in plant protection, as a propellant for airbags and in the defense sector, where customer interest has increased particularly significantly, continues to rise sharply. Since this demand can be subject to strong fluctuations, close ties to key customers and their long-term commitment are especially important to us.”


About Alzchem

Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem offers answers to various global developments such as climate change, population growth and increasing life expectancy. We deliver solutions through brands and products of the highest quality and through a sustainable vision to help shape global developments.

The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

Alzchem Group AG’s broad product range includes dietary supplements, precursors for PCR tests and pharmaceutical raw materials. These offerings are the company’s response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.

The company employs around 1,690 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and England. Alzchem generated Group sales of EUR 540.6 million and EBITDA of EUR 81.4 million in 2023.



02.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 2000683

 
End of News EQS News Service

2000683  02.10.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2000683&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Alzchem Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.